T. Rowe Price Associates
CDLX icon

T. Rowe Price Associates’s Cardlytics CDLX Stock Holding History

T. Rowe Price Associates’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,537
Closed -$75K – 3058
2025
Q2 		$75K Sell
4,537
-1,812
-29% -$31.3K ﹤0.01% 2948
2025
Q1 		$116K Buy
6,349
+102
+2% +$2.91K ﹤0.01% 2790
2024
Q4 		$232K Buy
6,247
+2,320
+59% +$88.8K ﹤0.01% 2616
2024
Q3 		$126K Buy
3,927
+770
+24% +$42.7K ﹤0.01% 2777
2024
Q2 		$260K Buy
3,157
+180
+6% +$19.5K ﹤0.01% 2489
2024
Q1 		$432K Buy
2,977
+177
+6% +$14.9K ﹤0.01% 2267
2023
Q4 		$258K Buy
2,800
+509
+22% +$51.7K ﹤0.01% 2440
2023
Q3 		$378K Sell
2,291
-707
-24% -$91.9K ﹤0.01% 2243
2023
Q2 		$190K Buy
2,998
+100
+3% +$6.06K ﹤0.01% 2549
2023
Q1 		$99K Buy
2,898
+660
+29% +$34.5K ﹤0.01% 2689
2022
Q4 		$129K Sell
2,238
-37
-2% -$2.29K ﹤0.01% 2659
2022
Q3 		$214K Buy
2,275
+517
+29% +$73.6K ﹤0.01% 2518
2022
Q2 		$392K Buy
1,758
+118
+7% +$39.5K ﹤0.01% 2323
2022
Q1 		$901K Buy
1,640
+110
+7% +$66.5K ﹤0.01% 2057
2021
Q4 		$1.01M Sell
1,530
-47
-3% -$35.9K ﹤0.01% 2035
2021
Q3 		$1.32M Buy
1,577
+95
+6% +$96.4K ﹤0.01% 1904
2021
Q2 		$1.88M Sell
1,482
-43
-3% -$48.5K ﹤0.01% 1762
2021
Q1 		$1.67M Buy
1,525
+253
+20% +$334K ﹤0.01% 1804
2020
Q4 		$1.82M Buy
1,272
+330
+35% +$352K ﹤0.01% 1675
2020
Q3 		$665K Sell
942
-128
-12% -$93.1K ﹤0.01% 1976
2020
Q2 		$749K Buy
+1,070
New +$618K ﹤0.01% 1904
2019
Q2 		– Sell
-6,738
Closed -$1.11M – 2543
2019
Q1 		$1.11M Buy
6,738
+2,885
+75% +$469K ﹤0.01% 1796
2018
Q4 		$417K Sell
3,853
-15,385
-80% -$2.59M ﹤0.01% 2147
2018
Q3 		$4.82M Buy
+19,238
New +$4.14M ﹤0.01% 1461

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
WPM
Worldly Partners Management Needham, Massachusetts $118M AUM 19.19% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $1.92B AUM 31.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

T. Rowe Price Associates's CDLX Position: Q3 2025 in Review

T. Rowe Price Associates sold out of Cardlytics (CDLX) in Q3 2025, closing a stake of 4,537 shares — an estimated $75K sold.

T. Rowe Price Associates first reported a position in CDLX in Q3 2018 and held it in 24 quarters. The position peaked at $4.82M in Q3 2018. 81 funds tracked by Wall St. Rank hold CDLX as of Q3 2025.

  • T. Rowe Price Associates reported no remaining Cardlytics position as of Q3 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 4,537 Cardlytics shares in Q3 2025, an estimated $75K.
  • T. Rowe Price Associates first reported a position in Cardlytics in Q3 2018 and held it in 24 quarters.
  • T. Rowe Price Associates's Cardlytics position peaked at $4.82M in Q3 2018.
  • 81 funds tracked by Wall St. Rank held Cardlytics as of Q3 2025.

Based on T. Rowe Price Associates's 13F filing for Q3 2025, filed 14 Nov 2025.